Updated
Updated · The National Law Review · Jul 7
Genetic LifeSpan Publishes 1 Peer-Reviewed Biological Age Review, Backing AgeCode Premier
Updated
Updated · The National Law Review · Jul 7

Genetic LifeSpan Publishes 1 Peer-Reviewed Biological Age Review, Backing AgeCode Premier

3 articles · Updated · The National Law Review · Jul 7

Summary

  • Genetic LifeSpan said its new peer-reviewed review article in the American Journal of Biomedical Science & Research supports broader clinical use of biological age measurement and its AgeCode Premier platform.
  • The paper examines DNA methylation, polygenic risk scoring, multi-omic biomarkers and organ-system aging, arguing biological age is more actionable than chronological age alone for assessing health and disease risk.
  • AgeCode Premier combines genomic analysis, DNA methylation and multi-system biomarker profiling to track biological aging, pace of aging, organ health and inherited predispositions.
  • The company says those tools could help physicians set baselines, personalize interventions and monitor outcomes as healthcare shifts toward earlier detection, prevention and longevity-focused care.

Insights

If biological age tests are the future, why do experts suggest cheaper blood panels offer more actionable, timely insights?
Is the booming biological age testing industry selling real science or just a number that fuels health anxiety?